Show simple item record

dc.contributor.authorAbedi-Ardekani, B
dc.contributor.authorDar, NA
dc.contributor.authorMir, MM
dc.contributor.authorZargar, SA
dc.contributor.authorLone, MM
dc.contributor.authorMartel-Planche, G
dc.contributor.authorVillar, S
dc.contributor.authorMounawar, M
dc.contributor.authorSaidi, F
dc.contributor.authorMalekzadeh, R
dc.contributor.authorHainaut, P
dc.date.accessioned2018-08-07T14:38:54Z
dc.date.issued2012-12-17
dc.identifier.citationBMC CANCER, 2012, 12
dc.identifier.issn1471-2407
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2285
dc.identifier.doi10.1186/1471-2407-12-602
dc.description.abstractBackground: Esophageal squamous cell carcinoma (ESCC) shows geographic variations in incidence, with high incidences (>50/10(5) person-years) in central Asia, including North Eastern Iran (Golestan) and Northern India (Kashmir). In contrast to Western countries, smoking does not appear to be a significant risk factor for ESCC in central Asia. In lung adenocarcinoma, activating mutations in the gene encoding epidermal growth factor receptor (EGFR) are frequent in tumors of never smokers of Asian origin, predicting therapeutic sensitivity to Egfr-targeting drugs. Methods: In this study 152 cases of histologically confirmed ESCC from Iran (Tehran and Golestan Province) and North India (Kashmir Valley) have been analyzed for EGFR mutation by direct sequencing of exons 18-21. Egfr protein expression was evaluated by immunohistochemistry in 34 samples from Tehran and HER2 mutations were analyzed in 54 cases from Kashmir. Results: A total of 14 (9.2%) EGFR variations were detected, including seven variations in exons. Among those, four (2.6%) were already documented in lung cancers, two were reported as polymorphisms and one was a potentially new activating mutation. All but one variation in introns were previously identified as polymorphisms. Over-expression of Egfr was detected in 22/34 (65%) of tested cases whereas no HER2 mutation was found in 54 cases from Kashmir. Conclusion: Overall, EGFR mutations appear to be a rare event in ESCC in high incidence areas of central Asia, although a very small proportion of cases may harbor mutations predicting sensitivity to anti-Egfr drugs.
dc.languageeng
dc.language.isoeng
dc.publisherBIOMED CENTRAL LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleEpidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia
dc.typeJournal Article
rioxxterms.versionofrecord10.1186/1471-2407-12-602
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2012-12-17
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBMC CANCER
pubs.notesaffiliation: Hainaut, P (Reprint Author), Int Agcy Res Canc, Lyon, France. Abedi-Ardekani, Behnoush; Dar, Nazir Ahmad; Martel-Planche, Ghyslaine; Villar, Stephanie; Mounawar, Mounia; Hainaut, Pierre, Int Agcy Res Canc, Lyon, France. Abedi-Ardekani, Behnoush; Saidi, Farrokh; Malekzadeh, Reza, Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Tehran, Iran. Abedi-Ardekani, Behnoush, Social Secur Org, Tehran, Iran. Dar, Nazir Ahmad, Univ Kashmir, Dept Chem, Srinagar 190006, Jammu & Kashmir, India. Mir, Mohammad Muzaffar, SK Inst Med Sci, Dept Clin Biochem, Srinagar, JK, India. Zargar, Showkat Ahmad, SK Inst Med Sci, Dept Gastroenterol, Srinagar, JK, India. Lone, M. Muqbool, SK Inst Med Sci, Dept Radiat Oncol, Srinagar, JK, India. Mir, Mohammad Muzaffar, Al Jouf Univ, Coll Med, Sakata 75471, Al Jouf, Saudi Arabia. Mounawar, Mounia, Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England. Hainaut, Pierre, Int Prevent Res Inst, Lyon, France. article-number: 602 keywords: Squamous cell carcinoma; Esophagus; EGFR mutations; Golestan; Kashmir keywords-plus: TYROSINE KINASE INHIBITORS; HIGH-RISK AREA; LUNG CANCERS; NORTHEASTERN IRAN; GENE-MUTATIONS; GEFITINIB; POPULATION; TP53; OVEREXPRESSION; AMPLIFICATION research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] researcherid-numbers: Abedi-Ardekani, Behnoush/O-7829-2016 Malekzadeh, Reza/U-1382-2017 Hainaut, Pierre/B-6018-2012 orcid-numbers: Abedi-Ardekani, Behnoush/0000-0002-0980-0587 Malekzadeh, Reza/0000-0002-9820-6335 Hainaut, Pierre/0000-0002-1303-1610 Malekzadeh, Reza/0000-0003-1043-3814 funding-acknowledgement: IARC; Programme National d’Expertise Specialisee on Lung Cancer, Institut National du Cancer, France funding-text: Nazir Ahmad Dar was supported by an IARC Post-Doctoral Fellowship. Work on EGFR at IARC is supported in part by the Programme National d’Expertise Specialisee on Lung Cancer, Institut National du Cancer, France. number-of-cited-references: 42 times-cited: 20 usage-count-last-180-days: 0 usage-count-since-2013: 9 journal-iso: BMC Cancer doc-delivery-number: 070HA unique-id: ISI:000313496000001 oa: gold da: 2018-08-07
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.volume12en_US
pubs.embargo.termsNot known
icr.researchteamMolecular Pathologyen_US
dc.contributor.icrauthorMounawar, Mouniaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0